Company: CERO
Filing Date: 2025-11-17
Form Type: PRE 14A
Source: 0001213900-25-111175
Chunk: 66

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-17
Form: PRE 14A
Chunk 66
---
 converted shares of Common Stock are referred to as “Conversion Shares” herein) at the fixed “Conversion Price” of $4.1625, which is subject to proportional adjustment upon the occurrence of any stock split, stock dividend, stock combination and/or similar transactions. Voluntary Adjustment Right.Subject to the rules and regulations of the Nasdaq, the Company has the right, at any time after the Stockholder Approval Date (as defined below), with the written consent of the Required Holders, to lower the fixed Conversion Price to any amount and for any period of time deemed appropriate by the board of directors of the Company (the “Board”). Alternate Optional Conversion.After the Stockholder Approval Date, at any time, at the option of the holder, the holder may convert the Series E Preferred Stock at the “Alternate Optional Conversion Price” equal to the lesser of: •The applicable Conversion Price, and •the greater of: •the floor price of $1.00 (the “Floor Price”); and •95% of the lowest volume weighted average price of the Common Stock during the five consecutive trading days immediately prior to such conversion. 36 Alternate Conversion Upon a Triggering Event.Following the occurrence and during the continuance of a Triggering Event (as defined below), each holder may alternatively elect to convert the Series E Preferred Stock at the “Alternate Triggering Event Conversion Price” (and together with the Alternate Optional Conversion Price, each an “Alternate Conversion Price”) equal to the lesser of: •The applicable Conversion Price, and •the greater of: •the Floor Price; and •90% of the lowest volume weighted average price of the Common Stock during the five consecutive trading days immediately prior to such conversion. The Certificate of Designations contains standard and customary triggering events (each, a “Triggering Event”), including but not limited to: (i) the suspension from trading or the failure to list the Common Stock within certain time periods; (ii) failure to declare or pay any dividend when due; (iii) the failure to timely file or make effective a registration statement on Form S -1or Form S -3pursuant to the Registration Rights Agreement (as defined below), (iv) the Company’s failure to cure a conversion failure or notice of the Company’s intention not to comply with a request for conversion of any Series E Preferred Stock, and (iv) bankruptcy or insolvency of the Company. Other Adjustments.In connection with the Private Placement, the Company has agreed to seek stockholder approval at a special meeting of stock